NCT05012371View on ClinicalTrials.gov

Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

February 16, 2022

Primary Completion Date

October 25, 2027

Study Completion Date

October 25, 2027

Conditions
Advanced Clear Cell Renal Cell CarcinomaMetastatic Clear Cell Renal Cell CarcinomaStage III Renal Cell Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8
Interventions
DRUG

Cabozantinib

Given PO

DRUG

Everolimus

Given PO

DRUG

Lenvatinib

Given PO

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (3)

22908

University of Virginia, Charlottesville

33612

Moffitt Cancer Center, Tampa

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER